These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 25133812)
1. Methodological recommendations for the diagnostics of EGFR gene mutations and ALK gene rearrangement in the selection of non-small-cell lung cancer patients to molecularly targeted therapies. Krawczyk P; Chorostowska-Wynimko J; Dziadziuszko R; Jassem J; Krzakowski M; Langfort R; Puacz E; Wasąg B; Wojas-Krawczyk K Pneumonol Alergol Pol; 2014; 82(5):437-44. PubMed ID: 25133812 [TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058 [TBL] [Abstract][Full Text] [Related]
3. Clinical and Cost Implications of Universal Versus Locally Advanced-Stage and Advanced-Stage-Only Molecular Testing for Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangements in Non-Small Cell Lung Carcinoma: A Tertiary Academic Institution Experience. Sauter JL; Butnor KJ Arch Pathol Lab Med; 2016 Apr; 140(4):358-61. PubMed ID: 27028394 [TBL] [Abstract][Full Text] [Related]
4. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance. Toyokawa G; Seto T Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376 [TBL] [Abstract][Full Text] [Related]
5. Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication. Rafael OC; Aziz M; Raftopoulos H; Vele OE; Xu W; Sugrue C Cancer Cytopathol; 2014 Jun; 122(6):454-8. PubMed ID: 24723383 [TBL] [Abstract][Full Text] [Related]
6. Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation. Choi CM; Kim MY; Hwang HJ; Lee JB; Kim WS Radiology; 2015 Apr; 275(1):272-9. PubMed ID: 25575117 [TBL] [Abstract][Full Text] [Related]
7. Molecular alterations in non-small cell lung carcinomas of the young. VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236 [TBL] [Abstract][Full Text] [Related]
8. Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations. Kim TJ; Lee CT; Jheon SH; Park JS; Chung JH Ann Thorac Surg; 2016 Feb; 101(2):473-80. PubMed ID: 26454747 [TBL] [Abstract][Full Text] [Related]
9. Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology. Marchetti A; Ardizzoni A; Papotti M; Crinò L; Rossi G; Gridelli C; Barberis M; Maiorano E; Normanno N; Taddei GL; Scagliotti G; Clemente C; Pinto C J Thorac Oncol; 2013 Mar; 8(3):352-8. PubMed ID: 23407559 [TBL] [Abstract][Full Text] [Related]
10. Rare mutations in non-small-cell lung cancer. D'Arcangelo M; D'Incecco A; Cappuzzo F Future Oncol; 2013 May; 9(5):699-711. PubMed ID: 23647298 [TBL] [Abstract][Full Text] [Related]
11. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695 [TBL] [Abstract][Full Text] [Related]
13. ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy. Rosell R; Karachaliou N; Wolf J; Ou SH Lancet Respir Med; 2014 Dec; 2(12):966-8. PubMed ID: 25466349 [No Abstract] [Full Text] [Related]
14. [Treatment of advanced non-small-cell lung cancer with driver mutations]. Tessmer A; Kollmeier J Dtsch Med Wochenschr; 2015 Mar; 140(5):323-8. PubMed ID: 25734673 [TBL] [Abstract][Full Text] [Related]
15. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment. Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382 [TBL] [Abstract][Full Text] [Related]
16. Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Gridelli C; Balducci L; Ciardiello F; Di Maio M; Felip E; Langer C; Lilenbaum RC; Perrone F; Senan S; de Marinis F Clin Lung Cancer; 2015 Sep; 16(5):325-33. PubMed ID: 25862554 [TBL] [Abstract][Full Text] [Related]
17. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. Lee JK; Kim TM; Koh Y; Lee SH; Kim DW; Jeon YK; Chung DH; Yang SC; Kim YT; Kim YW; Heo DS; Bang YJ Lung Cancer; 2012 Aug; 77(2):460-3. PubMed ID: 22622260 [TBL] [Abstract][Full Text] [Related]
18. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities. Gutierrez ME; Choi K; Lanman RB; Licitra EJ; Skrzypczak SM; Pe Benito R; Wu T; Arunajadai S; Kaur S; Harper H; Pecora AL; Schultz EV; Goldberg SL Clin Lung Cancer; 2017 Nov; 18(6):651-659. PubMed ID: 28479369 [TBL] [Abstract][Full Text] [Related]
19. The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre. Conde E; Angulo B; Izquierdo E; Muñoz L; Suárez-Gauthier A; Plaza C; Dominguez N; Torres M; Madrigal L; Rubio-Viqueira B; Belda-Iniesta C; Hidalgo M; López-Ríos F Histopathology; 2013 Mar; 62(4):609-16. PubMed ID: 23379755 [TBL] [Abstract][Full Text] [Related]
20. Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer. Baik CS; Chamberlain MC; Chow LQ J Thorac Oncol; 2015 Sep; 10(9):1268-1278. PubMed ID: 26107553 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]